Sign Up to like & get
recommendations!
1
Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.6_suppl.565
Abstract: 565Background: Erdafitinib is approved in pts with aUC with relevant FGFR2/3 GA. BLC2001 trials in pts with activating FGFR2/3 mutations reported 40% ORR to erdafitinib (49% for those with single n...
read more here.
Keywords:
genomic alterations;
fgfr2 genomic;
dna patients;
alterations cell ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2018 at "Oncotarget"
DOI: 10.18632/oncotarget.24975
Abstract: Trastuzumab-emtansine (T-DM1) is an antibody-drug conjugate that specifically targets HER2 thanks to its antibody component trastuzumab. In spite of responses to this novel agent, acquired resistance to treatment remains a major obstacle. Prolonged in vitro…
read more here.
Keywords:
prostaglandin pathway;
alterations cell;
adhesion;
cell adhesion ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.907994
Abstract: In multiple sclerosis (MS), relapse rate is decreased by 70-80% in the third trimester of pregnancy. However, the underlying mechanisms driving this effect are poorly understood. Evidence suggests that CD56bright NK cell frequencies increase during…
read more here.
Keywords:
cd56bright;
alterations cell;
multiple sclerosis;
pregnancy ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.1023606
Abstract: PAX5, a master regulator of B cell development and maintenance, is one of the most common targets of genetic alterations in B-cell acute lymphoblastic leukemia (B-ALL). PAX5 alterations consist of copy number variations (whole gene,…
read more here.
Keywords:
pax5;
leukemia;
pax5 alterations;
alterations cell ... See more keywords